McMaster University, Hamilton, Canada.
J Rheumatol. 2011 Nov;38(11):2342-5. doi: 10.3899/jrheum.110249. Epub 2011 Sep 1.
To describe early rheumatologic management for newly diagnosed rheumatoid arthritis (RA) in Canada.
A retrospective cohort of 339 randomly selected patients with RA diagnosed from 2001-2003 from 18 rheumatology practices was audited between 2005-2007.
The most frequent initial disease-modifying antirheumatic drugs (DMARD) included hydroxychloroquine (55.5%) and methotrexate (40.1%). Initial therapy with multiple DMARD (15.6%) or single DMARD and corticosteroid combinations (30.7%) was infrequent. Formal assessment measures were noted infrequently, including the Health Assessment Questionnaire (34.6%) and Disease Activity Score for 28 joints (8.9%).
Initial pharmacotherapy is consistent with guidelines from the period. The infrequent reporting of multiple DMARD combinations and formal assessment measures has implications for current clinical management and warrants contemporary reassessment.
描述加拿大新诊断类风湿关节炎(RA)的早期风湿科治疗方法。
对 2005-2007 年间从 18 个风湿病诊所随机选择的 339 名新诊断为 RA 的患者进行回顾性队列研究。
最常见的初始疾病修饰抗风湿药物(DMARD)包括羟氯喹(55.5%)和甲氨蝶呤(40.1%)。初始使用多种 DMARD(15.6%)或单一 DMARD 和皮质类固醇联合治疗(30.7%)并不常见。很少注意到正式的评估措施,包括健康评估问卷(34.6%)和 28 个关节疾病活动评分(8.9%)。
初始药物治疗与该时期的指南一致。很少报告多种 DMARD 联合和正式评估措施,这对当前的临床管理有影响,需要进行当代重新评估。